Investor Alert

Harrow Health Inc.



After Hours

 --Quotes are delayed by 20 min

May 20, 2022, 7:05 p.m.





0.00 0.00%


Volume 69,836

Quotes are delayed by 20 min


Previous close

$ 5.77

$ 5.90


+0.13 +2.25%

Day low

Day high




52 week low

52 week high




Mark L. Baum

Mr. Mark L. Baum is a Chief Executive Office & Director at Harrow Health, Inc. and a President at ImprimisRx TX, Inc. He is on the Board of Directors at Harrow Health, Inc., Mayfield Pharmaceuticals, Inc., Melt Pharmaceuticals, Inc., Surface Ophthalmics, Inc. and Surface Pharmaceuticals, Inc. Mr. Baum was previously employed as an Independent Director by Ideal Power, Inc., a President, CEO, CFO, Secretary & Treasurer by VisiTrade, Inc., a Chairman & President by PNG Ventures, Inc., a President, Chief Executive Officer & Director by Shrink Nanotechnologies, Inc., a Founder by Business Consulting Group Unlimited, a Chairman, President, CEO, CFO & Secretary by CoConnect, Inc., a Managing Director by The Baum Law Firm PC, a President by YesRx.com, Inc., a Chief Executive Officer & Director by Alpha Nutra, Inc., a Founder by Black Forest International LLC, a Chief Executive Officer & Director by Chembio Diagnostics, Inc., a Chief Executive Officer by China Media Networks International, Inc., a Chairman by ENDRA Life Sciences, Inc., a Co-Founder by Figa Group LLC, a President & Chief Financial Officer by Seven Stars Cloud Group, Inc., a President & Chief Executive Officer by Medical Solutions Management, Inc., a Founder by Noctua Fund LP, a Managing Member by Noctua Fund Manager LLC, a General Counsel by Quest Oil Corp., a Secretary, Chief Executive & Accounting Officer by Vision Dynamics Corp., a Member by State Bar of Texas, and a Member by The State Bar of California. He also served on the board at Eton Pharmaceuticals, Inc., Audiostocks, Inc., Applied Natural Gas Fuels, Inc., Metaphor Corp., Protokinetix, Inc. and Radley Pharmaceuticals, Inc. He received his undergraduate degree from California Western School of Law and an undergraduate degree from The University of Texas at Arlington.


Date Shares Transaction Value
01/20/2022 71,406   Derivative/Non-derivative trans. at $8.33 per share. 594,812
01/20/2022 125,000   Derivative/Non-derivative trans. at $2.4 per share. 300,000
04/25/2021 334,129   Derivative/Non-derivative trans. at $8.26 per share. 2,759,906
04/25/2021 850,000   Derivative/Non-derivative trans. at $0 per share. 0
02/25/2021 200,000   Derivative/Non-derivative trans. at $0 per share. 0
11/22/2019 156,000   279,240

Officers and Executives

Mr. Mark L. Baum
Chairman & Chief Executive Officer
Mr. Andrew R. Boll
Chief Financial Officer & Secretary
Dr. Larry M. Dillaha
Chief Medical Officer
Mr. Andrew Livingston
Chief Innovation Officer
Mr. John P. Saharek
Dr. Richard L. Lindstrom
Ms. Teresa F. Sparks
Independent Director
Dr. R. Lawrence van Horn
Independent Director
Mr. Perry J. Sternberg
Independent Director
Dr. Marty Makary
Independent Director
Link to MarketWatch's Slice.